Bluejay Diagnostics, Inc. (BJDX) · Nov 4, 2026 · Rights change

Bluejay reverse stock split takes effect as FDA work remains

1-for-4 reverse split — 4,468,051 shares reduced to approximately 1,117,013

Bluejay’s reverse stock split is now effective, reducing shares outstanding but offering no new FDA, clinical, or financing milestone.

Bluejay remains a pre-revenue, pre-FDA-clearance diagnostics developer trying to fund clinical work and move its Symphony sepsis-testing platform toward a 510(k) submission targeted for 2027. Its latest annual filing also described a need for substantial additional capital, making this a capital-markets action rather than a product milestone.

The reverse split is now operational, not transformative. The company implemented the 1-for-4 split effective November 3, 2026, reducing outstanding shares from 4,468,051 to approximately 1,117,013; warrants, equity awards, and reserved plan shares were adjusted proportionately.

November 3, 2026Before split
Common shares outstanding (Item 5.03)1,117,0134,468,051
Prefunded-warrant shares (Item 5.03)55,646222,581
Reverse-split ratio (Item 5.03)1-for-4—

This was already known before the filing. The board announced the 1-for-4 ratio on October 30, the effective date was set for November 3, and stockholders had already authorized the board to choose a split ratio at the June 9 annual meeting. The November 4 filing therefore confirms a scheduled corporate action rather than introducing a surprise. 〔0〕

The filing contains a minor internal inconsistency, but not a different economic outcome. The press-release exhibit says “every three” shares would be combined and lists 55,645 warrant shares, while the operative Item 5.03 description, the announced ratio, and the effective action state 1-for-4 and 55,646. That appears to be a drafting error in the exhibit, not a change to the completed split. 〔1〕

Bottom line: This is capital-structure housekeeping for a company still waiting on clinical and FDA progress. It changes the share count, not the underlying Symphony business story, so the event is routine and already anticipated.

What to watch next

SYMON-II clinical testing and 510(k) preparation in 2027

Original filing on SEC EDGAR

More Bluejay Diagnostics, Inc. news

Bluejay reverse stock split takes effect as FDA work remains | BJDX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.